Trump Proposes 100% Tariff on Foreign Generic Drugs by 2028

01The Story新闻事实

US President Donald Trump announced a phased tariff plan imposing 100% duties on generic drug imports in August 2028, doubling to 200% in 2029, to force pharmaceutical manufacturing back to the US.美国总统特��普拟于2028年8月对进口仿制药征收100%关税，2029年8月升至200%，旨在倒逼制药产能回流美国。

Generic drug imports receive a 2-year tariff grace period starting August 2026 before a 100% tariff takes effect in August 2028.自2026年8月起设2年关税豁免期，2028年8月起正式加征100%进口关税。
Import tariffs will escalate to 200% in August 2029 for manufacturers failing to establish domestic US production.未在美建厂企业的进口关税将在2029年8月进一步翻倍至200%。
Generic treatments account for more than 90% of all prescriptions filled in the United States.仿制药占美国处方药总量的90%以上。
India exported $10.5 billion in pharmaceuticals to the US in 2024-2025, making it the primary overseas generic supplier.印度是美国最��仿制药来源国，2024至2025财年对美药品出口额达105亿美元。

Forcing thin-margin generic pharmaceuticals to reshore via severe tariffs threatens US drug supply stability and risks sharp price increases for essential medicines.通过高额关税强推低毛利仿制药产能回流美��，将推高药物成本并引发供应链断裂风险。

024 Dimensions维度分析

Stakeholder impact利益相关方

Impact on Key Global Generic Exporters全球主要仿制药出口国受创

India and China supply the vast majority of finished generics and active pharmaceutical ingredients, making rapid replacement impossible.印中两国主导成品药及原料药供应，短期内本土替代难以实现。

Indian Pharmaceutical Exports to US印度对美药品出口额

10.5B USD105亿美元

2024-20252024-2025财年

Indian Share of US Birth Control Pills印度企业占美避孕药处方比例

65 %65%

20242024年

Duties would adversely affect over 40% of total Indian exports to the United States.关税将对印度超过40%的对美出口造成不利影响。
Two Indian companies, Glenmark and Lupin, manufactured 65% of all US birth control pill prescriptions in 2024.2024年美国65%的避孕药处方由格伦马克和路平两家印度企业生产。
Chinese factories supply critical US dependencies including antibiotics, blood thinners, and immunosuppressants.中国工厂供应美国抗生素、抗凝血剂及抗排异药物等关键品种。

Contradiction矛盾之处

Cost Dynamics and Industry Contradiction行业低毛利与高关税矛盾

Unlike patented drugmakers, generic manufacturers operate on low margins and cannot absorb high domestic manufacturing and tariff costs.与专利药企不同，仿制药商靠薄利多销，无力承受美国高昂建厂及关税成本。

Initial Import Tariff Rate初始进口关税税率

August 20282028年8月100 %

Major global generic producers Sandoz, Teva, and Viatris manufacture extensively outside the US to maintain low consumer prices.山德士、特华及伟达士等全球仿制药巨头主要在海外设厂以维持低价。
Sandoz CEO warned that aggressive US tariff shifts would raise drug prices and restrict patient access.山德士首席执行官警告称，美国高关税政策必将推高药价并削弱用药保障。

Cause因果关系

Policy Escalation and National Security Probes政策升级与国家安全调查

The tariff threat aligns with broader US trade probes and delayed enforcement timelines designed to force bilateral concessions.关税威胁结合了国家安全调查与延迟关税策略，旨在增加贸易谈判筹码。

US Prescriptions Supplied by Generics仿制药占美处方药比例

20262026年90 %

The US administration launched a national security trade probe into the pharmaceutical industry in April 2025.美国政府于2025年4月以国家安全为由对医药产业发起贸易调查。
A US-India trade agreement in February 2026 sought negotiated outcomes for generic medicines and ingredients.2026年2月美印贸易协议曾针对仿制药及原料药达成协商框架。

Future signal前瞻信号

Supply Shortage and Timeline Feasibility Risks产能迁移时限与断供风险

Industry experts note that building compliant pharmaceutical plants takes 4 to 5 years, far exceeding the two-year grace period.行业专家指出，合规药厂建设需4至5年，远超政府给出的2年过渡期。

2026-20282026-2028年 2 years2年

Pharmaceutical relocation requires strict regulatory approvals, equipment procurement, and supply chain validation.医药产能迁移需经严苛监管审批、设备采购及供应链验证。

03Timeline时间线

2025-04 US administration launches national security trade probe into pharmaceutical sector.美国政府对医药产业发起国家安全贸易调查。
2026-02 US and India strike trade agreement providing negotiated terms for generic drugs.美印达成贸易协议，就仿制药关税安排进行协商。
2026-07-21 Trump announces 100% generic drug import duty effective August 2028.特朗普宣布拟于2028年8月对进口仿制药开征100%关税。
2026-08-01 Two-year tariff exemption period officially begins for foreign generic manufacturers.海外仿制药制造商2年关税豁免期正式开启。
2028-08-01 100% import tariff takes effect for non-reshored generic pharmaceuticals.未回流本土生产的进口仿制药正式征收100%关税。
2029-08-01 Generic drug import tariff rate doubles to 200%.进口仿制药关税税率进一步翻倍至200%。

Key takeaway核心结论

Imposing prohibitive tariffs on imported generic pharmaceuticals threatens US drug affordability and supply security without guaranteeing successful onshore manufacturing reshoring.对进口仿制药征收惩罚性关税难以保障产能回流，反而严重威胁美国药物可负担性与供应安全。

04What to Watch后续关注

Specific terms of generic drug exemptions under the US-India bilateral trade pact.美印双边贸易协议中关于仿制药豁免的具体条款细则。
Corporate announcements on US manufacturing plant capital expenditures by foreign drugmakers.海外药企是否宣布在美国本土进行大规模产能建设计划。
Price trends and supply availability for common generic prescriptions ahead of 2026 midterms.2026年中期选举前常用处方仿制药的价格趋势与供应状况。

05Uncertainties不确定因素

Whether foreign drugmakers can secure FDA approvals and build US facilities within two years.海外药企能否在两年内完成FDA合规审批并建厂投产。
Legal challenges to the president's authority to impose broad tariffs on pharmaceutical products.针对总统对医药产品单边征收高额关税权的法律诉讼与争议。

06Sources信息来源

Trump’s 100% duty on generic drugs threatens US low-cost supply特朗普对仿制药征收100%关税威胁美国低成本药品供应 The Edge Malaysia · 2026-07-22
Trump Announces Phased Tariff Plan on Imported Generic Pharmaceuticals特朗普宣布对进口仿制药实施阶段性关税计划 Financial Times · 2026-07-21
Indian Pharma Industry Warns of Supply Chain Disruption Under US Tariff Proposal印度制药业警告美国关税提议将引发供应链动荡 Business Standard · 2026-07-22

Share this analysis 分享此深度分析

X Facebook LinkedIn WhatsApp